Theravance Biopharma TBPH 深 沪
已收盘 08-01 16:00:00 美东时间
10.90
-0.260
-2.33%
华盛通- 最 高11.06
- 今 开11.06
- 成交量 20.26万股
- 最 低 10.88
- 昨 收 11.16
- 总市值 5.45亿
- 52周最高 11.88
- 市盈率 静 --
- 换手率 0.41%
- 52周最低 7.86
- 委 比 -48.43%
- 总股本 5000.13万
- 历史最高 43.44
- 量 比 1.26
- 振 幅 1.61%
- 历史最低 6.10
- 每 手 1
- 风险率 0.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
DUBLIN, July 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2025 financial results and provide a business update after market close on Tues...
07-28 18:00
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
BTIG Maintains Buy on Theravance Biopharma, Raises Price Target to $25
BTIG analyst Julian Harrison maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and raises the price target from $24 to $25.
06-27 22:58
Theravance Biopharma Gains Milestone Payment from Viatris
Theravance Biopharma ( ($TBPH) ) has provided an announcement. On June 26, 2025...
06-26 18:28
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
Jones Trading Initiates Coverage On Theravance Biopharma with Buy Rating, Announces Price Target of $24
Jones Trading analyst Debanjana Chatterjee initiates coverage on Theravance Biopharma (NASDAQ:TBPH) with a Buy rating and announces Price Target of $24.
06-17 19:10
Theravance and Mylan settle patent dispute with Eugia Pharma
Theravance Biopharma (NASDAQ:TBPH) and partner Mylan reached a settlement agreement with Eugia Pharma over a patent dispute concerning the lung disease treatment, Yupelri inhalation solution. The comp...
06-06 21:11
美股牛股 | 受益于美国大幅提高钢铁关税，克利夫兰克里夫涨超23%、世纪铝业涨超21%
美国大幅提高钢铁关税，克利夫兰克里夫涨超23.2%、世纪铝业涨超21.3%；Applied Digital大涨48%，与CoreWeave达成长期租赁协议>>
06-03 19:21
Theravance Biopharma Secures $225M In Cash From GSK Deal, Bringing Total Trelegy Monetization Value To $1.525B
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026,
06-02 18:07
